IP Library › Granted Patent US 12,239,702
Granted Patent B2
US 12,239,702 · App. 16/769,329 · Granted Mar 4, 2025

Vaccination with replicon particles and oil adjuvant

Inventors: Mark A. Mogler (Ames, IA); Erin Strait (Spring Hill, KS); Ruud Philip Antoon Maria Segers (Boxmeer, NL)
Assignee: INTERVET INC.
A61K39/193A61K9/1075A61K47/26A61K9/0021A61K2039/53A61K2039/55566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,702
App. No.
16/769,329
Granted
Mar 4, 2025
Kind
B2
Abstract

The present invention relates to vaccination against animal pathogens using alphavirus-replicon RNA particles and oil adjuvants. To a vaccine, and a kit of parts comprising the replicon particles and the oil adjuvant. Also to methods and uses of making and using the vaccine and the components of the kit.

Claims (19)

1. A vaccine comprising an alphavirus RNA replicon particle encoding an antigen originating from an animal pathogen, wherein the vaccine also comprises an oil adjuvant which comprises a mineral oil and a non-mineral oil, wherein the mineral oil is a liquid paraffin oil and wherein the non-mineral oil is Vitamin E acetate.

2. The vaccine of claim 1 , wherein the amount of the mineral oil in the oil adjuvant is 1-70% v/v of the oil adjuvant.

3. The vaccine of claim 1 , wherein the total amount of the non-mineral oil in the oil adjuvant is 0.1-30% w/v of the oil adjuvant.

4. The vaccine of claim 2 , wherein the oil adjuvant is formulated as an oil-in-water emulsion.

5. The vaccine of claim 1 , wherein the alphavirus RNA replicon particle is a Venezuelan Equine Encephalitis (VEE) alphavirus RNA replicon particle.

6. The vaccine of claim 5 , wherein the encoded antigen originating from an animal pathogen is an antigen originating from a pathogen of an animal selected from the group consisting of a fish, an avian, and a mammal.

7. The vaccine of claim 6 , wherein the mammal is a porcine.

8. The vaccine of claim 6 , wherein the avian is a chicken or a turkey.

9. The vaccine of claim 6 , wherein the fish is a member of the Cichlidae family.

10. A kit comprising at least two containers, wherein at least one container comprises an alphavirus RNA replicon particle encoding an antigen originating from an animal pathogen, and at least one container comprises an oil adjuvant, which comprises a mineral oil and a non-mineral oil; wherein the mineral oil is a liquid paraffin oil and wherein the non-mineral oil is Vitamin E acetate.

11. A method of immunizing an animal comprising administering to the animal immunologically effective amounts of the vaccine of claim 1 .

12. The method of claim 11 , wherein the animal is a fish and the encoded antigen originating from an animal pathogen is an antigen originating from a fish pathogen.

13. The method of claim 11 , wherein the animal is a mammal and the encoded antigen originating from an animal pathogen is an antigen originating from a pathogen of a mammal.

14. The method of claim 13 , wherein the mammal is a porcine and the antigen originating from a pathogen of a mammal is an antigen originating from a pathogen of porcine.

15. The method of claim 11 , wherein the alphavirus RNA replicon particle and the oil adjuvant are administered in or on the target animal body in simultaneous use or in concurrent use.

16. A method of making the vaccine of claim 1 comprising the step of admixing the alphavirus RNA replicon particle encoding an antigen originating from an animal pathogen, and the oil adjuvant.

17. The method of claim 16 , wherein the alphavirus RNA replicon particle is comprised in an aqueous solution.

18. The method of claim 17 , wherein the volume ratio (v/v) of the aqueous solution and the oil adjuvant is between 1:2 to 2:1.

19. The method of claim 17 , wherein the volume ratio (v/v) of the aqueous solution and the oil adjuvant is about 1:1.

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2020
From: MOGLER, MARK A.; STRAIT, ERIN; SEGERS, RUUD PHILIP ANTOON MARIA
To: INTERVET INC.
Reel/Frame 052823/0261 →
Continuity (3)
Provisional Application 62607101 · Dec 18, 2017
Provisional Application 62594342 · Dec 4, 2017
Related Publication 20200323975A1 · Oct 15, 2020
References Cited (54)
US 7561972B1 · Welch et al. · 2009 [cited by applicant]
US 7561973B1 · Welch et al. · 2009 [cited by applicant]
US 7805252B2 · Gustafsson et al. · 2010 [cited by applicant]
US 8126653B2 · Welch et al. · 2012 [cited by applicant]
US 8425922B2 · Vajdy · 2013 [cited by examiner]
US 8460913B2 · Kamrud et al. · 2013 [cited by applicant]
US 9441247B2 · Rayner et al. · 2016 [cited by applicant]
US 20110300205A1 · Geall · 2011 [cited by examiner]
US 20120237543A1 · Hayes et al. · 2012 [cited by applicant]
CN 1798760A · 2006 [cited by applicant]
CN 102348466A · 2012 [cited by applicant]
CN 103154737B · 2015 [cited by applicant]
EA 020962B1 · 2015 [cited by applicant]
EP 0382271A1 · 1990 [cited by applicant]
EP 2471926A2 · 2012 [cited by applicant]
EP 2471926A3 · 2012 [cited by applicant]
JP 11269093A · 1999 [cited by applicant]
JP 2004516333A · 2004 [cited by applicant]
JP 2013531680A · 2013 [cited by applicant]
JP 2014522840A · 2014 [cited by applicant]
RU 2580299C2 · 2016 [cited by applicant]
TW 201300537A · 2013 [cited by applicant]
WO 2002053181A1 · 2002 [cited by applicant]
WO 2005007689A1 · 2005 [cited by applicant]
WO 2009144088A2 · 2009 [cited by applicant]
WO 2011008548A1 · 2011 [cited by applicant]
WO 2011049677A1 · 2011 [cited by applicant]
WO 2012006380A2 · 2012 [cited by applicant]
WO 2012025612A1 · 2012 [cited by applicant]
WO 2013006834A1 · 2013 [cited by applicant]
WO 2013131565A1 · 2013 [cited by applicant]
WO 2013152086A1 · 2013 [cited by applicant]
WO 2014005958A1 · 2014 [cited by applicant]
WO 2016038197A1 · 2016 [cited by applicant]
WO 2017162741A1 · 2017 [cited by applicant]
WO 2018115435A1 · 2018 [cited by applicant]
Allison AC. Squalene and squalane emulsions as adjuvants. Methods. Sep. 1999;19(1):87-93. doi: 10.1006/meth.1999.0832. PMID: 10525443. (Year: 1999). [cited by examiner]
Anderson, Tavis K. et al., Population dynamics of cocirculating swine influenza A viruses in the United States from 2009 to 2012, Influenza and Other Respiratory Viruses, 2013, 42-51, 7 (Suppl. 4). [cited by applicant]
Bredenbeek, Peter J. et al., Sindbis Virus Expression Vectors: Packaging of RNA Replicons by Using Defective Helper RNAs, Journal of Virology, 1993, 6439-6446, 67(11). [cited by applicant]
Davis, NL et al., Alphavirus replicon particles as candidate HIV vaccines, IUBMB Life, 2002, pp. 209-211, 53. [cited by applicant]
International Search Report for PCT/EP2018/083297 mailed on Feb. 20, 2019, 13 pages. [cited by applicant]
Kamrud, K.I. et al., Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle, Journal of General Virology, 2010, 1723-1727, 91(Pt 7). [cited by applicant]
Liljestrom, P. et al., A new generation of animal cell expression vectors based on the semliki forest virus replicon, Biotechnology, 1991, pp. 1356-1361, 9. [cited by applicant]
Lundstrom, Kenneth, Alphavirus-Based Vaccines, Viruses, 2014, 2392-2415, 6. [cited by applicant]
Polo, J.M. et al., Alphavirus DNA and particle replicons for vaccines and gene therapy, Dev. Biol., 2000, 181-185, 104. [cited by applicant]
Pushko, Peter et al., Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes in Vitro and Immunization against Heterologous Pathogens in Vivo, Virology, 1997, 389-… [cited by applicant]
Sandbulte, Matthew R. et al., Analyzing Swine Sera for Functional Antibody Titers Against Influenza A Neuraminidase Proteins Using an Enzyme-Linked Lectin Assay (ELLA), Methods in Molecular Biology, 2014, 337-345, 1161. [cited by applicant]
Vajdy, Michael et al., Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines, Immunology and Cell Biology, 2004, 617-627, 82. [cited by applicant]
Vander Veen, RL et al, Alphavirus replicon vaccines, Animal Health Research Reviews, 2012, 1-9, vol. 13, No. 1. [cited by applicant]
A. Franchini, Vitamin E in viral inactivated vaccines, Poult. Sci, Apr. 1994, pp. 666-671, vol. 74 , No. 4. [cited by applicant]
Wanasawaeng, W., et al., Development of inactivated Newcastle disease vaccine using palm oil as an adjuvant, The Thai Journal of Veterinary Medicine, 2009, 9-16, 39. [cited by applicant]
Eggen et al., 2010, “One-dose vaccination against M. hyo and PCV2,” Pig Progress, Jun. 8, 2010 [online] [retrieved on Jun. 18, 2024]. Retrieved from the Internet :<URL: https://www.pigprogress.net/health-nutrition/one-d… [cited by applicant]
Karlsson et al., 2017, “Increased humoral immunity by DNA vaccination using an α-tocopherol-based adjuvant,” Hum. Vaccin. Immunother., 13(8):1823-1830. [cited by applicant]
Schultz-Cherry et al., 2000, “Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses,” Virology, 278(1):55-59. [cited by applicant]